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Abstract: There are presently no reliable ways to quantify human pancreatic beta cell mass (BCM)
in vivo, which prevents an accurate understanding of the progressive beta cell loss in diabetes or
following islet transplantation. Furthermore, the lack of beta cell imaging hampers the evaluation of
the impact of new drugs aiming to prevent beta cell loss or to restore BCM in diabetes. We presently
discuss the potential value of BCM determination as a cornerstone for individualized therapies
in diabetes, describe the presently available probes for human BCM evaluation, and discuss our
approach for the discovery of novel beta cell biomarkers, based on the determination of specific splice
variants present in human beta cells. This has already led to the identification of DPP6 and FXYD2γa
as two promising targets for human BCM imaging, and is followed by a discussion of potential safety
issues, the role for radiochemistry in the improvement of BCM imaging, and concludes with an
overview of the different steps from pre-clinical validation to a first-in-man trial for novel tracers.
Keywords: beta cell imaging; MRI; pancreas; PET; pre-clinical validation; radiochemistry; SPECT;
type 1 diabetes; type 2 diabetes
1. Beta Cell Mass Evolution during Type 1 and Type 2 Diabetes
Diabetes currently affects 420 million people worldwide, and this prevalence is projected to
increase to 642 million people by 2040 [1]. The disease is associated with high morbidity, causing
five million deaths annually worldwide [1]. Diabetes-related deaths are primarily due to cardiovascular
diseases (50%) and kidney failure (10–20%) [2–4]. Diabetes is also the leading cause of blindness in
working adults and contributes to 50% of lower limb amputations [5]. Type 1 diabetes (T1D, around
10% of the cases) is caused by a progressive and eventually nearly complete loss of beta cell mass (BCM)
following autoimmune destruction [6,7]. In contrast, type 2 diabetes (T2D, 85% of the cases) is caused
by a failure of pancreatic beta cells to compensate for insulin resistance in peripheral tissues [8].
This form of the disease is typically associated with obesity and leads to progressive beta cell failure
due at least in part to chronic metabolic stress [8]. The clinical diagnosis of diabetes relies on the
detection of elevated blood glucose levels or the surrogate marker HbA1C (glycated hemoglobin) [9].
T1D patients are treated by multiple daily injections of insulin to control blood glucose levels. In some
cases, i.e., recipients of a kidney graft or patients affected by recurrent and severe hypoglycemia, islet
transplantation is an option, allowing partial recovery of endogenous insulin secretion and, in most
cases, transitory independence from exogenous insulin administration [10,11]. The initial therapies for
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T2D rely on lifestyle changes (weight loss and exercise) and the use of drugs stimulating the release of
endogenous insulin and/or increasing the peripheral sensitivity to this hormone, with the eventual
addition of exogenous insulin [9].
Both T1D and T2D are characterized by a reduced BCM [6–8,12,13], but the natural history
of beta cell loss in these diseases, as well as the relationship between BCM and function, remains
unclear. This is due to a lack of adequate tools for the in vivo quantification of human BCM. Currently,
most studies are limited to pancreatic specimens from necropsy. Given the medical complications
and ethical restrictions associated with pancreatic biopsy, this method is not a viable approach for
measuring BCM. In T1D, the autoimmune attack against pancreatic beta cells results in progressive
and nearly complete loss of these cells [14–16]. However, many studies reported the existence of
remaining beta cells and detectable C-peptide in the circulation in >30–80% of long-duration T1D
patients [17–20]. In T2D patients, the decrease in BCM is more modest (by 22–63%) [21,22]. In both
forms of diabetes, BCM loss is preceded by progressive loss of beta cell function, as was confirmed
by studies performed on pancreas slices from T1D organ donors [23]. It is thought that many beta
cells are preserved as quiescent or “stunned” cells (i.e., degranulated or not releasing insulin) in both
T2D [24] and T1D [17,18,25]. This represents a challenge for histological determination of BCM in tissue
specimens as beta cells may still be present but missed when anti-insulin staining is used. Therefore,
BCM is probably often underestimated [26,27].
The beta cells that may still be viable in diabetic patients are, therefore, good targets for future
pharmaceutical interventions. How these residual beta cells influence the course of the disease is
currently unknown. Do they help stabilize glycemia, reduce the rate of diabetes complications,
or prevent severe episodes of hypoglycemia? It is crucial to underline that clinical diabetes depends not
only on the absolute amount of beta cells but also on the function of the individual beta cells. Patients
with diabetes or impaired glucose tolerance tend to have a lower BCM, but the BCM by itself does
not necessarily predict the glucose tolerance of individual patients. Whether knowledge of BCM in
relation to beta cell function helps to predict if and when an individual will develop diabetes, and who
will respond or not to certain therapies, remain to be defined [28].
2. Beta Cell Imaging Is a Cornerstone for Future Individualized Treatment of Diabetes
The great Brazilian poet Mario Quintana once remarked, “The correct answer is irrelevant: the essential
is that the questions are correct”. However, to reach successful human beta cell imaging, we will need both
correct questions and correct answers. The best present approach to quantify BCM is medical imaging.
This technique is non-invasive, fast, safe, quantitative, and can be used repeatedly in the same patients.
Medical imaging machines are also widely available. Beta cell imaging would be ideal at patient
diagnostics to identify the best-suited therapeutic strategies based on the remaining BCM, to ensure the
patient’s follow-up, and to assess their responses to novel therapies aiming to prevent beta cell loss or
to restore BCM. For example, it would help to identify those individuals with T2D that would benefit
from therapies relying on the presence of a large amount of viable, potentially insulin-secreting beta
cells, such as sulfonylureas or GLP-1 (glucagon-like peptide-1) analogs, while others with very limited
beta cell reserve may directly change to insulin replacement. In the case of T1D, the presence of a good
reserve of non-functional beta cells may indicate the use of anti-inflammatory agents (e.g., cytokine
blockers) in parallel to insulin therapy, with the hope of restoring some endogenous insulin release [29].
BCM imaging could also be used to assess the survival of islets or pancreas grafts and to guide the
selection of immunosuppressive treatments to reduce graft rejection. Beta cell imaging would also
be crucial to enhance our understanding of the pathophysiology and disease progression of both
T1D and T2D. Finally, beta cell imaging could be an invaluable tool for drug development, used for
the validation of new therapeutic compounds aiming to restore BCM and function. By helping in
the stratification of patient cohorts, it would help to reduce costs, improve clinical trial reliability,
and reduce the clinical trial attrition rate. Ideally, these methods should be used in parallel of C-peptide
determination, which would allow the detection of both functional beta cells (beta cell mass and
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stimulated C-peptide are in agreement) and non-functional beta cells (beta cells are present, but there
is no or very low stimulated C-peptide).
Despite this clear potential, the ideal beta cell-specific imaging probe has yet to be identified.
This can be explained by the many obstacles hampering the development of such techniques. One of the
major obstacles is that beta cells constitute only 1–3% of the total pancreatic mass and are heterogeneously
distributed throughout the pancreas into the small islets of Langerhans (100–300 µm in diameter) [30].
Islets themselves are composed of multiple cell types, including beta (~60%), alpha (~30%), delta (~10%),
PP (pancreatic polypeptide), epsilon, endothelial, and neuronal cells [30]. There are also marked
inter-individual differences in BCM independently of disease [13,22,31], and BCM mass in people
with T2D has substantial overlap with BCM of non-diabetic individuals and patients with impaired
glucose tolerance [32]. Finally, beta cell dysfunction(s) and the pro-inflammatory environment in T1D
or the metabolic stress in T2D lead to considerable changes in gene expression profile [14,33–36], which
complicates the identification of a biomarker suitable for beta cell quantification across disease states.
Therefore, the ideal probe/target should be exquisitely beta cell-specific and sensitive enough to allow
discrimination between healthy individuals and diabetic patients without being affected by beta cell
stress secondary to disease pathogenesis.
Currently, attempts at in vivo visualization of beta cells in humans rely on radiolabeled tracer
molecules that bind to beta cells with different degrees of specificity [37]. These radiotracers can
be detected at the picomolar range by two techniques: positron emission tomography (PET) and
single-photon emission computed tomography (SPECT) (see details below, in part 8.). Although
the spatial resolution of both types of scanners does not allow resolving single islets [38], beta
cell quantification by imaging actually does not require the resolution of single islets. Indeed,
the “visualization” of beta cells is based on the high specificity and the biochemical/metabolic
characteristics of the tracer molecule (chemical resolution) [37,39] that provides an estimation of the
total beta cell mass. These techniques must be used in conjunction with anatomical imaging techniques
such as magnetic resonance imaging (MRI) or computed tomography (CT) [38], which allows organ
segmentation, an useful method to ascertain the origin of the PET or SPECT signal. For BCM imaging,
PET is preferred over SPECT as both the resolution and the sensitivity of clinical PET imagers are higher
than SPECT instruments (4–5 mm and >10 mm, respectively) [38]. MRI alone has also been used for
BCM quantification and visualization. While MRI exhibits excellent resolution (<0.5 mm), this degree
of resolution is not widely available clinically [38]. Furthermore, this method suffers from lack of
sensitivity and requires the accumulation of probes in the micromolar range [40], which currently
limits its use for BCM imaging. In light of the continuous technology improvement in the field [41],
it is conceivable that MRI-based technologies for visualization of islets in humans will become widely
available in the coming years.
3. BCM Probes Presently under Clinical Investigation
During the last decade, several putative beta cell-specific probes have been identified, including
monoclonal antibodies (mAbs) [42,43], short or fragments of antibodies [44,45], peptides [46–48], small
molecules such as metabolites [49–51], and ion-binding probes [52,53]. The different existing tracers
have been recently and comprehensively reviewed [54] and will not be further discussed here. Amongst
this variety of probes, only three families of radiotracers are currently undergoing clinical evaluation
in humans: 18F-dihydro-tetrabenazine (DTBZ) for imaging of vesicular monoamine transporter
2 (VMAT2) [49,55], 11C-hydroxytryptophan (HTP) as a marker for the serotonergic system [50],
and 111In- and 68Ga-labeled exendin-4 and derivatives targeting the GLP-1 receptor [46].
Exendin-4 and derived molecules are presently the most promising approach for BCM
imaging. Many studies performed in rodents found a tight correlation between BCM and
exendin-4-associated signal [56,57]. This probe is highly sensitive and can be used to detect as
few as 50 rat islets transplanted intramuscularly in mice [58]. Exendin-4 can also be used to monitor
endogenous BCM evolution in mice after drug intervention. Thus, after nine weeks of canagliflozin
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treatment (a sodium-glucose transporter-2 inhibitor), an increase in BCM and accumulation of
[Lys12(111In-Bn-diethylenetriaminepenta-acetic acid(DTPA)-Ahx)]exendin-4 was observed in mice [59].
The same probe was also used to assess the protective effect of DS-8500a (a novel G protein-coupled
receptor-119 agonist) on BCM in db/db mice, a model of severe insulin resistance and diabetes [60].
Importantly, insulitis does not affect the binding of [111In]In-DTPA-exendin-3 in NOD (non-obese
diabetic) mice [61], but high glucose leads to decreased GLP-1 expression and consequent exendin
binding [62]. Exendin-4-based probes are often used in conjugation with SPECT or PET but attempts
to generate MRI probes have also been made. Recently, exendin-4 was conjugated to dodecane
tetraacetic acid (DOTA) and conjugated with gadolinium (Gd) and was used to discriminate between
healthy and β-cell-depleted C57BL/6J mice [63]. Altogether, these data suggest that exendin-4 is
sufficiently specific and sensitive to be used for longitudinal BCM quantification in rodents, including
during early diabetes. However, despite these promising results, studies performed in humans
indicate some limitations. Thus, there was only a decrease by 40–60% of the exendin-derived signal in
long-term T1D patients [56], which are expected to show a >90–95% decrease in BCM [64]. Possible
explanations for this are: 1. GLP-1R expression may not be sufficiently beta cell-specific in humans.
Indeed, this receptor was found expressed in alpha cells [65] and recent studies using super-resolution
microscopy and fluorescent exendin-4 derivatives confirmed that GLP-1R is present in at least 5% of
alpha cell population [66]. Low levels of expression were also found in other pancreas-surrounding
tissues such as the intestine, stomach, lung, and kidneys [67,68], which could increase the background
signal; 2. Another intriguing possibility is that exendin-4 detects non-functional beta cells, but this
remains to be proven.
A similar lack of specificity was observed with the other probes currently under clinical
investigation. Only 30% of the 18F-DTBZ signal originated from beta cells, the remaining 70%
coming from the other pancreatic endocrine cells [69,70]. Another study found a moderate signal
decrease (+/−50%) in type 1 diabetic patients using [18F]FP-(+)-DTBZ and PET imaging [55,71], while
no difference was observed for type 2 diabetic patients [55]. A substantial and highly significant
reduction in pancreas uptake was found in type 1 diabetic patients imaged with [11C]-HTP [50],
but conflicting studies reported that HTP also accumulates in other pancreatic endocrine or exocrine
cells [72]. Even if these probes may not be specific enough to quantify BCM with sufficient accuracy,
they could be repurposed for the detection of insulinomas or the follow-up of islets grafts. In line with
this, a recent study proved the efficiency of exendin-4 to detect insulinomas [73].
In conclusion, and in spite of the promising results with the tracers described above, there remains
a clear need for the discovery of novel and more specific biomarkers to improve the potential for
radiotracer based BCM imaging.
4. Detection of Transplanted Human Islets by MRI
As mentioned above, islet transplantation is a possible therapy for type 1 diabetes, particularly in
patients affected by severe and recurrent hypoglycemia. Since the publication of the Edmonton
protocol for immunosuppression, the success rate of islet transplantation in humans has
improved [74]. A long-term endogenous insulin production and glycemic stability can be achieved
in many patients, although insulin independence is progressively lost in spite of continuous
immunosuppression [10,11,75,76]. Graft survival and function are usually assessed by measuring
circulating C-peptide, glycemia and glycated hemoglobin, but imaging could provide additional and
valuable information on the remaining beta cell graft mass. Techniques such as bioluminescence or
fluorescence imaging have been developed in rodents [77–79], but are difficult to translate to humans.
Promising results have been obtained with the use of MRI to detect islets prelabeled with paramagnetic
metals. For instance, MRI was used to quantify iron oxide-labeled allogeneic islets grafted under the
kidney capsule or injected in the portal vein of baboons [80]. Superparamagnetic beads were also
used to label islets and to successfully monitor the grafts in rodents [81–83]. Paramagnetic beads
can also be conjugated with other molecules to form bifunctional probes. For instance, human islets
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were pre-loaded with beads conjugated to a small interfering RNA directed against caspase 3 and
transplanted in baboons, which helped to maximize graft viability and to minimize the number of
donor islets required [84]. There are concerns that the use of iron will contribute to catalyze the
generation of oxygen free radicals, but available data suggest that human islet pre-labelling do not
affect islet cell viability or beta cell function [85], although it requires a prolonged culture time which
may increase the risk of infection. An alternative approach would be to use paramagnetic beads
conjugated to antibodies. For instance, immunomagnetic beads coated with an antibody targeting the
rat MHC class I antigen was used with success to image rodent islets grafted in rat liver [85].
Another approach involves encapsulating human islets into pre-labeled biocompatible capsules.
For instance, iron oxide nanoparticles encapsulated within alginate hydrogel capsules containing
viable islets were developed and successfully used in mice [86]. These capsules can be retrieved using
a magnetic field and a dedicated retrieval device. MRI imaging can also be used to detect periportal
steatosis, a possible complication of intraportal islet transplantation [87]. A concern regarding the
techniques described above is the relative low stability of these beads in vivo. For instance, in humans
prelabeled islets were detected by MRI only up to 24 weeks [88]. Therefore, this technique is better
suitable for the short-term detection of grafted human islets: other imaging techniques are needed for
the long-term follow-up of recipients of islet allografts. Probes presented in part 3 could be used for
this purpose.
5. New Experimental Approaches to Identify Beta Cell Biomarkers
Many of the biomarkers identified so far originated from high-throughput analyses, such as
RNA sequencing or proteomics. Genes/proteins preferentially expressed in beta cells are selected and
validated in vitro and in vivo. Of note, most studies up to now focused on whole gene expression,
which limits the number of possible hits. Alternative splicing is an mRNA processing mechanism
that leads to the generation of multiple transcripts from a single gene [89–91]. As this process is cell
type-dependent [89], many transcripts are likely to be expressed in beta cells only.
Another possible drawback is related to the way beta cell-specific probes are usually designed
and tested. First, the probes are developed and validated in vitro by using binding and competition
studies performed on cells overexpressing the gene of interest or directly on the targeted cells. Second,
the probes are functionalized for imaging, labeled, and used to image endogenous rodent BCM or
rodent islets grafted in rodent models. In case of success, the probes are then tested in human cells.
This approach has, however, important limitations. There are many differences between species,
and genes are often differentially expressed in mice and humans [92], including in beta cells [93].
Even in the case where genes are similarly expressed in both rodents and humans, the protein
homology, including post-translational changes, is often limited. For the beta cell-specific probes based
on metabolites, the pathophysiological differences existing between humans and other species are
also a limiting factor [94–97]. Therefore, a robust biomarker in rodents may not be specific in humans.
Probes designed against mouse proteins are also likely to present a lower affinity for the human protein
due to weak homology. As molecular imaging is often based on the use of small molecules, the impact
of amino acid differences across species is theoretically higher [98].
Our group has approached the discovery of novel beta cell biomarkers by combining two proposed
complementary approaches, namely, using human islets or beta cells from the start and focusing
on the identification of specific splice variants present in human beta cells, but not in other human
tissues [34,35,45,99,100]. Our present approach for biomarker discovery is shown in Figure 1. Only the
plasma membrane proteins (or those with an unknown cellular location) that are not modified by
exposure to the proinflammatory cytokines IL-1β, IFN-γ and IFN-α, or by metabolic stress (i.e., exposure
to high glucose and/or saturated free fatty acids as palmitate), are considered for further validation.
The rationale for this is that islets are probably exposed to these stresses during the course of diabetes [8]
and we wish to avoid stress-induced changes in the expression of our biomarkers. So far, we identified
two biomarkers by using this or a similar approach: dipeptidyl peptidase 6 (DPP6) [45] and FXYD
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domain-containing ion transport regulator 2γ (FXYD2γ) variant a [47,48]. We have developed imaging
probes for each of them, based on small camelid antibodies (nanobodies, Nb) [45,101] or small proteins
generated by phage display [47], respectively.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 28 
 
protein in beta cells remains to be determined. DPP6 autoantibodies were found associated with 
e cephalitis and neurologic disorders in humans [104]. We have shown that DPP6 expression is 
restricted to beta cells, with a mild expression in alpha cells and a low level of expression in neurons, 
and that decreased DPP6 expression is present in long-term type 1 diabetic patients [45,101]. RNA 
sequencing data suggests that DPP6 expression is higher and better correlated to the expression of 
insulin than the GLP-1 receptor [45,101]. Of note, DPP6 is also highly expressed in insulinomas [45] 
and may become a novel biomarker for detecting these difficult-to-diagnose tumors. 
 
Figure 1. Step-by-step workflow presently used by our group to identify new beta cell biomarkers 
and to generate corresponding imaging probes. A schematic overview of the methodology used to 
mine RNA sequencing data for discovery of novel pancreatic islet biomarkers is shown. Transcripts 
differentially expressed in pancreatic islets are identified by comparing transcriptomes of human 
pancreatic islets against 16 different normal human tissues. Deep RNA sequencing analysis (>180 
million reads, to allow identification of >80% splice variants) is performed on untreated human islet 
preparations or after treatment with pro-inflammatory cytokines (IL-1β + IFN-γ or IFN-α) or exposure 
to metabolic stress (high glucose and/or palmitate) to identify transcripts unaltered by the stressful 
conditions prevailing in diabetes. A software analysis (Ingenuity pathway analysis (IPA) analysis + 
transmembrane domain) is conducted on the generated hits to identify membrane-expressed 
proteins, potentially reachable with a probe. Once the biomarkers identified are validated at the 
mRNA and protein levels, one or more imaging probes are developed. After complete in vitro 
validation, the probes are tested for in vivo imaging on humanize mouse models grafted with 
different amounts of human beta cells. 
To develop an anti-DPP6 probe, we used an innovative approach based on a camelid antibody, 
named nanobodies (Nb) [45]. These small (10–14 kDa) antibodies display unique features with 
respect to size, stability, and versatility [105,106]. They present thus advantages over the 10-times 
- -ste workflow presently used by our group to identify new b ta cell biomarkers nd to
generate cor esponding imaging probes. A sch matic overview of the methodology used t mine RNA
sequencing data for discovery of novel pancreatic islet biomarkers is shown. Tran cripts differentially
expressed in pancreatic islets are ident fi d by comparing transcriptomes of human pancreatic islets
against 16 diff rent normal human tissues. Deep RNA sequencing analysis (>180 million re ds, to allow
identification of >80% splice v ria ts) is perform d on untreated hu an islet preparations or aft r
treatment with pro-infl mmatory cytokines (IL-1β+ IFN-γ or IFN-α) or exposure to metabolic stress
(high glucose and/or palmitate) to identify transcripts unaltered by the stressful con itions prevailing
in diabetes. A software analysis (Ingenuity pathwa analysis (IPA) analysis + transmembrane domain)
is conducted on the generated hits to identify membrane-expressed proteins, potentially reachable with
a probe. Once the biomarkers identified are validated at the mRNA and protein levels, one or more
imaging probes are developed. After complete in vitro validation, the probes are tested for in vivo
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The DPP6 gene encodes for a transmembrane protein of 98 kDa characterized by a short intracellular
tail and a massive extracellular domain of 728 amino acids [102], which makes it a good candidate for
targeting with imaging probes. In neurons, DPP6 acts as a regulatory subunit of the voltage-gated
A-type Kv4.2 potassium channel complex, helping to stabilize it [103]. The role of this protein in
beta cells remains to be determined. DPP6 autoantibodies were found associated with encephalitis
and neurologic disorders in humans [104]. We have shown that DPP6 expression is restricted to
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beta cells, with a mild expression in alpha cells and a low level of expression in neurons, and that
decreased DPP6 expression is present in long-term type 1 diabetic patients [45,101]. RNA sequencing
data suggests that DPP6 expression is higher and better correlated to the expression of insulin than the
GLP-1 receptor [45,101]. Of note, DPP6 is also highly expressed in insulinomas [45] and may become a
novel biomarker for detecting these difficult-to-diagnose tumors.
To develop an anti-DPP6 probe, we used an innovative approach based on a camelid antibody,
named nanobodies (Nb) [45]. These small (10–14 kDa) antibodies display unique features with respect
to size, stability, and versatility [105,106]. They present thus advantages over the 10-times larger
traditional antibodies. For instance, based on their unique pharmacokinetics it is possible to image
mice 60 min post Nb injection [45], while imaging with mAbs is ideally performed 2–4 days post
administration [107]. This timing also allows the use of radioisotopes with a shorter half-life. With an
apparent biological half-life estimated to 3–4 h [108], most of the Nb is quickly cleared from the
patient’s body via the urinary system, avoiding prolonged exposure to radioactive isotopes or possible
probe-associated cytotoxic effects. By using SPECT and an anti-DPP6 probe, we successfully imaged
mice grafted with tumors formed by cells overexpressing the protein of interest [45]; human clonal beta
cells (EndoC-βH1) [45]; and human islets [101] (Figure 2). Furthermore, dose-response experiments
using immune-deficient mice grafted with different numbers of EndoC-βH1 and human islets indicated
a significant positive correlation between the probe uptake and the number of cells grafted [101].
However, due to the limited sensitivity of SPECT imaging, only the largest number of transplanted
cells (>5 × 106 cells or >3000 islet equivalents) provided a significantly higher signal as compared to
the background signal observed following grafts of exocrine pancreatic tissue (which may still contain
a small amount of islet cells) [101]. Future efforts will aim to adapt the anti-DPP6 Nb to PET imaging
to improve sensitivity and quantitation. A first experiment, performed on NOD-SCID (Nonobese
diabetic/severe combined immunodeficiency) mice grafted with human neuroblastoma cells naturally
expressing DPP6 and imaged with 68Ga-radiolabeled anti-DPP6 Nb, confirmed better performance as
compared to the previous version of the probe [101].
The second biomarker identified belongs to the FXYD protein family, which is composed of single
transmembrane proteins containing an FXYD motif at their N-terminus [109]. The gene encoding
FXYD2γ can produce two splice variants: FXYD2γa and FXYD2γb that only differ by their first exon
(8 amino acids) encoding the extracellular N-terminal extremity of the protein [109]. FXYD2γa is
predominantly expressed in kidney tubule cells, but limited expression is also observed in salivary
and mammary glands, dorsal root ganglia, and pancreas [99,110]. FXYD2γ is the γ subunit of the
Na+/K+ ATPase and regulates its activity by inducing ion channel activity by direct binding to the
α subunit [109]. By controlling the activity of this ATPase, FXYD2γ is involved in the generation of
the resting membrane potential in neurons and Na+ reabsorption in kidneys [111]. Hyperosmotic
shock triggers the expression of FXYD2γa in proximal tubule cells [112], and FXYD2γa may play a
role in the regulation of mechano-sensitivity in rodent cells [113,114]. While the function of FXYD2γa
in neurons seems well defined, its role in beta cells remains to be clarified. FXYD2γ knock-out mice
display beta cell hyperplasia and glucose intolerance, suggesting that this protein plays a role in
endocrine pancreas physiology [110]. FXYD2γa expression is restricted to beta cells and appears
early during fetal development [99], which makes it one of the most specific beta cell biomarkers
identified so far. To target FXYD2γa for imaging purposes, we generated a short peptide, P88, by using
phage display and functionalized it for MRI by conjugation to ultra-small particles of iron oxide
(USPIO) [47] or Gd-DOTA [48]. By using these probes, we were able to detect tumors constituted of
cells overexpressing the target [47,48], or EndoC-βH1 [48]. Unfortunately, the limited sensitivity of the
probe associated with the use of MRI hinders the possibility of detecting BCM and of quantifying their
size. Future efforts will be focused on the adaptation of P88 to PET imaging and the generation of a
labeled nanobody targeting FXYD2γa.
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Besides their potential utility for imaging, the beta cell biomarkers described above may be useful
to deliver protective cargo to the beta cells, including the targeting of regulatory T cells (that have
the potential to decrease insulitis) to the islets [115]. In another potential application, expression of
FXYD2γa in exosomes derived from human beta cells allowed the noninvasive monitoring of rejection
of islet allografts [116]. This suggests that FXYD2γa and other specific beta cell biomarkers may allow
capturing beta cell-derived vesicles from the serum, with the potential of enabling the following of
beta cell destruction via circulating markers. If confirmed, this approach would provide an interesting
complement to beta cell imaging and functional tests.
6. Other Innovative Approaches for Beta Cell Imaging
Present attempts at BCM quantification by imaging relies on the use of single techniques, such as
PET-CT or MRI, and is thus limited to the quantification of only one parameter, the BCM. However,
as described above, the function of the remaining beta cells could be hampered by an underlying
process such as inflammation and/or severe metabolic stress (“stunned beta cells”) [8]. It would be
thus advantageous to use multiple imaging parameters in parallel to asses both beta cell mass and
function. Multimodal imaging techniques could enable this goal. A recent study combined the use of
two techniques, e.g., MRI and PET imaging [117] based on two different probes, namely manganese (Mn)
ions (Mn ions enter beta cells via voltage-dependent calcium channels that are activated in response to
glucose metabolism and are thus a potential surrogate for the steps leading to glucose-induced insulin
release) and exendin-4 (to quantify BCM) [117]. By this approach, it was shown an increase in both
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BCM and function in mice that spontaneously develop insulinomas [117]. Despite these promising
results, the study had limitations that could hamper its clinical translation. First, exendin-4 and Mn
ions accumulation must be quantified at different time points (1 and 24 h, respectively) [117]. Second,
clinical use could be limited by the potential neurotoxicity of Mn2+ [118,119]. Moreover, data were only
generated in mice, and feasibility remains to be demonstrated in humans. Another proposed approach
is to detect Zn2+ ions accumulation in insulin granules. By using a gadolinium-based Zn2+-sensitive
agent and MRI it was possible to detect “hot spots” in the abdomen of mice after glucose injection that
co-localized with islets as analyzed by histology [53]. The sensitivity of this technique is low, but this
approach may become viable with the continuous improvements of MRI instrumentation, and could
be used in the future in combination with agents that quantify BCM.
Quantification of insulitis is also an exciting approach to follow up the autoimmune assault
in T1D and to estimate the effect of immunosuppressive drugs, particularly if measured in parallel
with BCM. Probes used in other fields could be repurposed for this goal. For instance, USPIOs are
known to accumulate in macrophages in atherosclerotic lesions [120]. Such magnetic nanoparticles
and MRI imaging were used to predict with success the onset of diabetes in NOD mice [121]. In mice,
fluorescently labeled paramagnetic beads were used to track and visualize microvascular leakage
in NOD mice [122]. Ferumoxtran-based USPIOs were used to detect insulitis in early-onset T1D
patients [123], although the signal increase was moderate (2-fold) [123]. Another interesting tool in this
context is to use tracers that bind to PDL1 (Programmed death-ligand 1), presently under development
for tumor imaging [124]. Pancreatic beta cells exposed to the inflammatory environment of T1D, but not
control beta cells, express high amounts of PDL1, probably as an attempt to fend off the autoimmune
assault [125]. Thus, imaging PDL1 using non-blocking antibodies could provide an accurate estimation
of the islets under immune-mediated attack.
7. Could the Beta Cell Imaging Be Deleterious for Beta Cells?
The validation of tracers for BCM imaging must go hand in hand with careful considerations
of safety. First, many T1D patients are children, who should not be exposed to excessive radiation.
Second, the probes to be used must not present any cytotoxicity against beta cells (i.e., no effect on
cell viability, insulin secretion, and DNA integrity), nor stimulate the autoimmune reaction present
in type 1 diabetes. Third, the immunogenicity of BCM imaging agents should be low as repetitive
imaging sessions will be required to ensure the patient’s follow-up. Fourth, as most of the present
techniques rely on the use of PET or SPECT, which require radioisotopes, the radiation level should
be kept as low as possible. For instances, concerns were reported about the non-specific uptake of
exendin-4 derivatives in the kidneys, and therefore radiation dosimetry. A similar concern could be
risen regarding other small-size probes such as Nbs or metabolites that are cleared via the urinary tract.
Importantly, independent groups using differently radiolabeled forms of exendin-4 did not detect beta
cell or renal toxicity [126,127], and Nbs targeting DPP6, at doses 50-fold higher than the ones present
in vivo, did not affect human beta cell survival or function [101]. More recently, a study performed on
six patients with hyperinsulinemic hypoglycemia showed that the effective dose of exendin-4 for BCM
imaging was 0.71 ± 0.07 mSv (for an injection of 100 MBq) [128]. Since the present maximal annual
acceptable radiation exposure for adults in Europe is 20 mSv [129], the technique would be safe for this
population. The dose would be however higher in newborns (2.32 ± 0.32 mSv, annual limit = 1 mSv)
but decreases rapidly with age (<0.77 mSv in 1-year old children) [128]. Several methods have been
suggested to limit kidney probe uptake and radiation exposure, such as pre-administration of lysine,
gelofusine, or polyglutamic acid [130], or use of a cleavable linker that can be removed by kidney
cells [131,132].
8. Radiochemistry—Appending Imaging Isotopes to Beta Cell Probes
Over the last half century, there has been rapid and widespread growth in the use of nuclear imaging
driven by the availability of nuclear imaging isotopes and development of novel radiopharmaceuticals,
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many of them considered for BCM imaging (see above). Nuclear imaging primarily consists of
two imaging techniques, PET and SPECT. While there have been efforts to use SPECT in beta-cell
imaging [43,45,46,56,57,133], we will focus here on the chemistry of PET isotopes. PET is a nuclear
imaging technique used to visualize functional physiological or pathological processes in the body.
This is accomplished through the use of unstable isotopes which undergo nuclear β+ decay. As part of
this nuclear decay process, PET isotopes emit positrons (antimatter counterpart of electrons) which
annihilate with electrons located millimeters away, resulting in the emission of two coincident 511 keV
gamma photons in opposite directions. A PET scanner measures these gamma photons with respect
to time resulting in high spatial resolution of the annihilation event. These annihilation events are
reconstructed in silico to produce a three-dimensional image of the tracer concentration within the body
over time. When coupled with anatomical imaging techniques, such as CT or MRI, the localization of
tracer uptake can be further defined.
Traditionally, the design of radiopharmaceuticals for PET was confined to a few isotopes; carbon-11,
nitrogen-13, oxygen-15, and fluorine-18. With improvements in both cyclotron availability, targetry and
automated synthesis and purification chemistries, the incorporation of alternative isotopes, especially
radiometals, into nuclear imaging probes has drastically increased. With the vast array of radionuclides
presently available from both locally sourced cyclotron facilities and commercial distributors of
longer-lived isotopes, the choice of radionuclide must work in concert with the chemical form of the
unlabeled ligand (small molecule, peptide, antibody, etc). Once the modality and ligand chemistries
are known, the radionuclide selection can be narrowed based on other properties such as radioactive
half-life (t1/2), ease of chemical synthesis, and required in vitro and in vivo properties. A wide variety
of nuclear imaging isotopes have been employed in tracers geared towards beta cell imaging.
Since carbon is the backbone of all organic molecules essential to life, incorporation of carbon-11
(11C, t1/2 = 20.4 min) is an obvious choice for many PET tracers as the chemistry is straightforward
and no changes are made to the parent structure or its pharmacological properties. 11C is produced
from high-energy proton bombardment of naturally occurring nitrogen-14 on a cyclotron; addition
of a small amount of O2 gas affords [11C]CO2 as the primary source for 11C chemistries. There are
numerous 11C synthons that may be derived from [11C]CO2, many of which can be prepared on
commercially available synthesis modules including [11C]MeI, [11C]MeOTf, [11C]CO, and [11C]HCN.
However, 11C has a relatively short half-life, requiring efficient chemistry with incorporation of the
11C-label occurring at or near the end of the synthesis to minimize loss of radioactivity. Furthermore,
availability is limited to local production facilities as the short half-life restricts the ability to distribute
these tracers. Several tracers developed as surrogate markers of beta-cell mass have utilized 11C for use
with PET including [11C]DTBZ [49], [11C]5-HTP [50], [11C]AZ12204657 [134], and [11C]MK7246 [135].
With the widespread clinical use of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), fluorine-18
(18F, t1/2 = 109.8 min) is the most frequently used PET nuclide. 18F is typically prepared on
a cyclotron through proton bombardment of oxygen-18 enriched water. The aqueous fluoride
solution from the cyclotron is formulated with aqueous potassium carbonate and the crown ether
Kryptofix® 222 to chelate the potassium counter-ion and enhance the reactivity of the fluoride
ion. The chemistries to incorporate 18F have been extensively reviewed [136–139]. The most
common radiofluorination technique is nucleophilic substitution of halides or sulfonates by the
[18F]-fluoride ion. Since fluoride is not a strong nucleophile in aqueous solution, the [18F]-fluoride
is dehydrated prior to the reaction to further enhance reactivity. The longer half-life of 18F relative
to 11C allows for more complex, multi-step syntheses, extended imaging times, and distribution of
tracers beyond the site of preparation. Furthermore, the prevalence of fluorinated pharmaceuticals
has drastically increased in recent years as the substitution of hydrogen or a hydroxyl group
for fluorine in biologically active small molecules is generally well tolerated. Thus, 18F can be
incorporated into small molecules with little to no change in biological activity. Several 18F-tracers have
been evaluated for their ability to quantify beta cell mass including 18F-exendin analogs [140],
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5-(2-[18F]-fluoroethoxy)-L-tryptophan [141], [18F]fluoropropyl-(+)-DTBZ [71], 18F-mitiglinide
derivatives [142], and 18F-repaglinide derivatives [143].
The radiometal gallium-68 (68Ga) PET has garnered much attention in recent years,
particularly following FDA approval of two 68Ga agents (68Ga-DOTATATE (DOTA-0-Tyr3-Octreotate)
and 68Ga-DOTATOC (DOTA0-Phe1-Tyr3)octreotide)) and the success of 68Ga-agents targeting
prostate-specific membrane antigen (PSMA) in prostate cancer clinical studies. Despite a relatively
short half-life of 68 min, 68Ga tracers are readily deployed as preparation of the 68Ga isotope is not
dependent on a cyclotron. Commercial gallium-68 generators extract 68Ga from a source of decaying
germanium-68 (68Ge, t 1/2 = 271 days). Given the inherent finite lifetime of gallium generators,
solutions have been developed to prepare 68Ga on demand from a cyclotron via proton bombardment
of an aqueous solution of zinc-68 [144]. Unlike carbon-11 and fluorine-18, 68Ga-labeling requires
the use of a chelator to attach the radiometal to the desired ligand, as described in excellent reviews
detailing the coordination chemistry and the application of specific chelators [145–147]. The most
common 68Ga-chelators include the macrocycles DOTA and 1,4,7-triazacyclononane-1,4,7-triacetic
acid (NOTA). Once the conjugation of the chelator to the ligand is complete, the complex is combined
with an aqueous solution of 68Ga to capture the radiometal. By conjugating the chelator prior to the
introduction of the radiometal, the labeling process is significantly shortened. This also allows for the
use of a broad range of imaging agents, including small molecules, peptides, and antibody fragments.
Numerous tracers incorporating 68Ga to image beta-cell mass have been reported, including exendin-4
derivatives [148,149], octreotide derivatives [150], and DPP6-targeting nanobodies [101].
An emerging application of PET imaging, dubbed immuno-PET, uses radiolabeled mAbs as the
diagnostic targeting vector. With the optimization of cyclotron targetry and methodology, zirconium-89
(89Zr) has emerged as an optimal isotope for immuno-PET imaging. 89Zr is typically produced from
high-energy proton bombardment of an Yttrium-89 solid target (Yttrium foil over aluminum/copper
disc). The decay half-life of 89Zr (3.3 days) matches the typical in vivo pharmacokinetics of mAbs to
give an optimal signal to background ratios. Similar to other radiometals, 89Zr labeling of antibodies
requires the use of a chelator chemically linked to the antibody, with desferrioxamine B (DFO-B)
being the most common chelator for 89Zr labeling. The long half-life of 89Zr also allows for the broad
commercial distribution of the isotope. The increasing availability of 89Zr has led to more clinical
studies of 89Zr tracers with promising results. While the number of 89Zr tracers specifically targeting
beta cells is limited, there have been successful feasibility studies utilizing 89Zr-labeled mAbs targeting
transmembrane protein 27 [151].
While imaging with 89Zr-mAbs can provide outstanding affinity and target specificity, the long
half-life of 89Zr could be deleterious to beta cells due to prolonged radiation exposure. To mitigate the
prolonged exposure to radiation from 89Zr, pretargeting approaches may be used. Pretargeting takes
advantage of biorthogonal click chemistry in vivo between trans-cyclooctenes conjugated to mAbs and
tetrazine-based small molecules [152–154]. In this approach, the modified antibody is administered,
followed by a delay period of 24–72 h to allow time for the antibody to circulate and engage the desired
target. The radiolabeled tetrazine-containing small molecule probe that recognizes and specifically
binds to the transcyclooctenes of the modified antibody is then administered. This system combines
the favorable pharmacokinetic properties of small molecule tracers with the affinity and specificity of
antibodies. As such, short-lived isotopes such as 18F, 64Cu, and 68Ga, which are normally not compatible
with antibody imaging due to the mismatch of the short half-life of the isotope and the long in vivo
circulation times of the mAb, are now viable alternatives to 89Zr for mAb imaging. This approach
could prove to be extremely valuable for beta cell imaging as a method to obtain specificity while
simultaneously reducing radiation exposure to the beta cells.
9. From Preclinical Validation to First in Man Testing—Checking all the Required Steps
Conventional pharmaceuticals are a class of compounds designed to bind selectively and with
high affinity to an epitope of interest in the target tissue, with the intent of altering the disease-relevant
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biological processes while minimizing the off-target (i.e., non-specific) binding and associated toxicity.
When combined with appropriate dose amount and frequency, the result is a drug, which has excellent
target tissue exposure, minimal metabolism, and low off-target toxicity. Therefore, the primary goal of
developing conventional pharmaceuticals is the efficacy and safety profile of the drug. By contrast,
molecular imaging probes represent a special class of pharmaceuticals, which retain the selectivity
and affinity of traditional pharmaceuticals but because they are often labeled with radioisotopes [155],
require dose levels that are far below the amount required to elicit either a pharmacological or
toxicological response [155], and typically operate at levels significantly below the No Effect Level
(NOEL) [155,156]. This microdosing approach is only possible if the specific activity (i.e., the activity
per quantity of a radionuclide) is sufficiently high to permit non-invasive detection while minimizing
the on-target effect of the unlabeled probes mass [157,158]. As such, the primary objective of the
imaging probe is the non-invasive detection of the physiological process, which underlies the disease
progression (i.e., pathophysiology), and/or therapeutic response, which modifies the disease trajectory
(i.e., pharmacodynamic biomarker), without altering the state of this system. To achieve this, molecular
imaging probes should possess the following characteristics:
• High target binding affinity. This characteristic is among the most important attributes of an
imaging probe since the binding of the agent to the epitope of interest is one of the key features
that promote tissue accumulation. To achieve high tissue uptake within the mean resonance time
of the tracer in the primary circulation, the tissue binding must exhibit fast on- (kon) and slow off-
(ko f f ) rate constants for the target epitope.
• High target specificity. Target specificity ensures that the molecular probe is reporting only the
target of interest and the underlying physiological processes, but also plays a role in improving
the signal-to-noise ratio (SNR) of the resulting image. Low specificity agents have high off-target
(i.e., non-specific) binding, thus increasing the apparent “noise” floor of the image, which is
unrelated to the physiological processes, thus making visualization and quantification of the
image more difficult.
• High target sensitivity. In order to detect the pathophysiology of the disease process at the early
stages, where the epitope of interest may be at low concentration, the molecular probe should have
high sensitivity. In other words, trace quantities of the probe must be able to bind to the target with
high affinity and specificity (see above), such that they produce an image that can differentiate the
underlying pathology from normal physiological function. Implicit in this is that the molecular
probe must function at trace concentrations, such that it does not elicit a pharmacological response
(i.e., administered in trace quantities) and is below the toxicological NOEL.
• High in vivo stability. Despite the fact that only trace amounts of the imaging probe are
administered to the subject, it is critical that the structure remains intact since numerous enzymes
and proteases are present in the blood, liver, and target tissue. If a compound undergoes
transformation, then the three-dimensional structure of the probe will change, thus affecting
the binding of the compound to the pocket and epitope of interest. Moreover, if a compound
undergoes cleavage because of its metabolism, and the dynamics of this new metabolite are
ignored, or not accounted for, the interpretation of the subsequent images are significantly biased
by the presence of the new metabolite(s).
• High contrast to noise ratio. Image contrast is also a key factor to consider when developing a
molecular imaging probe. To achieve this, images typically have high SNR and low off-target
binding (i.e., low non-specific), which yields target-to-background ratios suitable for the detection
of trace quantities in the target tissues. Moreover, imaging probes should have kinetics that
favors rapid uptake and slow washout rates in the target tissue, while non-target tissues show
preferentially fast washout rates. This differential rate is in part related to the wash-in kinetics,
affinity of the ligand to the target, and low non-specific binding to non-target tissues.
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• Low toxicity and immunogenicity. Since imaging probes are a special class of pharmaceutical
administered in trace quantities, toxicity is rarely an issue. However, if an imaging probe is
composed of a labeled biologic, e.g., antibodies or nanobodies, immunogenicity can present a
unique set of challenges, since repeat administration could result not only in an immune response,
thus rendering the targeting inactive, but also lead to severe allergic reactions.
• Low production costs. The cost of imaging probes production is governed in part by the cost
of the starting materials, cost of cyclotron beam time, and labor associated with reaction series.
Of particular importance pre-clinically is the selection of the nuclide: the longer the half-life,
the greater numbers of products that can be derived from a production run, and the broader the
distribution range of the formulated drug products.
In an effort to evaluate if a novel imaging agent retains the above-listed characteristics, the majority
of molecular imaging probes undergo rigorous in vitro and in vivo testing to determine their
physiochemical, kinetic, and biological properties. In the in vitro phase, there are several overlapping,
interactive and recursive stages in the evaluation of imaging probes, which include the establishment
of assay conditions, validation of the assay, testing novel ligands in the assay, and quantitative analysis
of the resulting data to derive binding parameters [159].
Recent advances in assay miniaturization and the use of 96, 384, or 1536 well plates permits
the high throughput screening (HTS) of large numbers of molecular probes in a single plate [160].
In these assays, the concentration of receptors per unit volume is maximized, while the concentration
of radioligand is kept to a minimum to reduce costs and increase assay sensitivity [160]. When using
high-affinity molecular ligands, there is a risk that the binding of ligand to the receptor will result in a
reduction in the free ligand concentration (i.e., ligand depletion), thus violating the assumption that free
ligand concentration is equal to the concentration added [160]. Instead, the free ligand concentration
should be measured directly, where the concentration of receptors should be less than 10% of the
ligand’s equilibrium dissociation constant (Kd), and thus ideally, less than 10% of the ligand will be
bound to the receptor of interest [161]. Importantly, these assay conditions are often incompatible
with miniaturization formats, resulting in a conflict between precision and practicality. An alternative
approach is to take radioligand depletion into account [162–164]; however, it is suggested that these
analyses should only be used in assays with less than 50% ligand depletion [163].
Once the relationship between the ligand and the concentration of the receptor has been established,
the determination of the molecular probe affinity may be performed. Under standard conditions,
receptor binding reactions follows the law of mass action according to:
L + R↔ L·R (1)





[L] ∗ [R] ∗ ko f f
[L·R] ∗ kon
(2)
where, [L], [R], [L·R], ko f f , kon, and Kd are the concentration of the ligand, the concentration of
the receptor, concentration of the ligand/receptor complex, dissociation rate constant, association
rate constant, and equilibrium dissociation constant, respectively [165]. Importantly, molecular
probes showing binding to the target site, which are typically limited in their quantity and
distribution [166–168], are, therefore “specific” and saturable at increasing concentrations of the
radioligand, while probes which bind to off-target sites are “non-specific” and have virtually unlimited
binding sites [159,162,165,169]. Using this construct, several methods have been developed for the
determination of the affinity of a ligand for its target.
The most direct approach is the application of saturation binding, where the total binding is
determined as a function of the concentration of the ligand of interest [164,166,167]. To accurately
determine the affinity, the radiotracer concentrations should range from 10-fold below to 10-fold above
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the expected Kd [166]. Moreover, to determine the degree of non-specific binding, studies have shown
that if the assay is conducted at 100–1000 fold above the Kd (i.e., excess cold/unlabeled), the binding
curve is linearly dependent of dose [164,165]. Provided this, the specific binding can be determined
by subtracting the non-specific amount, and then analytically modeling the curves. In early studies,
this modeling was performed by linearizing the data by plotting the bound versus bound/free and
fitting the equation of a line through the data, where the slope of the line is equal to −1/Kd, and the
intercept with the X-axis is an estimate of maximum density of binding sites (Bmax) [170]. Although
this approach is useful for visualizing data, it suffers from inaccuracies that violate the assumptions of
linear regression, thus impacting the Kd and Bmax estimates [165,168]. Modern approaches utilize
direct modeling via non-linear regression [165], where the data are plotted as the concentration of the





where Bmax, Kd, and [L] are the maximum density of binding sites, the equilibrium dissociation rate
constant, and the concentration of the ligand. Unlike the linearization, this approach has been shown
to correctly estimate the rate constants without introducing bias and does not violate the primary
assumptions of dependency and normal distribution of the data [159,165].
Under conditions where the supply of radioligand is limited, estimates of affinity can be determined
via competitive binding, where a single concentration of a radiolabeled ligand is used in the presence
of various concentrations of unlabeled ligand, where the logarithm of the unlabeled ligand is plotted
against the total ligand binding. Under these conditions, the estimate of total binding can be determined
via non-linear regression of the following
Y = NS +
(T −NS)
1 + 10([L]−log 10(IC50))
(4)
where NS, T, [L], log 10, and IC50 are the nonspecific binding, total binding, concentration of unlabeled
ligand, logarithm base 10, and inhibitory concentration at 50%, respectively. Provided this, and if
the Kd of the labeled is known, equilibrium dissociation constant for inhibitory studies (Ki) can be
computed based on Chang-Prusoff transformation [171].
In order to understand the association (i.e., on-rate) and dissociation (i.e., off-rate) of the labeled
molecular probe to the receptor system, kinetics studies with time can be performed independently for
each, or combined as a single study [165]. Under conditions of a single combined study, the receptor
system is loaded with radioligand, and periodic measurements are made with time until equilibrium
has been achieved [164,165]. At equilibrium, the receptor system is centrifuged, re-suspended in fresh
buffer, and 100–1000 fold unlabeled ligand is added. This is followed by a detailed analysis of the
assay until the new equilibrium has been achieved [164,165]. From this time course, the association














) ∗ (1− e(−1∗[L]∗kon+ko f f ∗tn)) ∗ e(−1∗[L]∗ko f f (t−tn)) (5)
where t, tn, Bmax, [L], kon, and ko f f are the time, equilibrium time when the excess unlabeled is added,
the maximum density of binding sites, labeled ligand, association (“on”) rate constant, and dissociation




binding potential (Bp; konko f f ) [172] can be derived. Molecular probes that have high affinity and the
likelihood of advancing to in vivo studies typically have a Kd of <50 nM [159,165], specific binding
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(i.e., specific/non-specific of >5 fold) and a Bp > 0.02. Recent work from our lab has combined the
traditional association-dissociation studies this with miniaturization and autoradiography to permit a
single plate determination of kon and ko f f rates [173].
Once a molecular probe has been well characterized via the aforementioned in vitro assessments
and has been shown to exhibit high affinity (i.e., <50 nM), favorable association and dissociation
kinetics (i.e., kon  ko f f ), in vivo studies, can be performed in model systems, such as mice implanted
with human pancreatic islets. These studies typically encompass selecting an animal model which
exhibits the biology of interest (e.g., tracers targeting splice variants are often species-specific and
cannot be evaluated in mouse tissues), and therefore the receptor system to image, and performing
medical imaging of the radiotracer via PET (or SPECT). Most molecular probes are neither covalently
bound to their target nor are functionally trapped in the tissues [174,175]. Thus, in order to understand
the kinetics of the radiotracer, studies must be performed via dynamic acquisition, where three-
dimensional (3D) images with time (i.e., four-dimensional image series) are acquired to permit
non-invasive monitoring of the molecular probe. In this acquisition scheme, vascular access is acquired
prior to the subject being placed on the scanning bed and advanced to the center of the scanner’s
field of view (FOV). After collection of attenuation correction scans via computed tomography (CT),
the PET (or SPECT) scanner acquisition sequences start to permit several seconds of data acquisition
prior to tracer administration and are then continued for 45–60 min. Starting the scanner prior to
administration of the molecular probe permits the collection of images during the arterial phase of
the tracer kinetics and is critical for subsequent tracer kinetic modeling. At the completion of the
acquisition phase, 3D image series are reconstructed into discrete time bins with a reverse logarithmic
spacing (i.e., 0, 1, 2, 3, 4, 8, 16, 24, 36, 48, 60 min), yielding a series of image volumes suitable to
capturing the appearance of the tracer in the arterial tree with time that tracks the bio-distribution of
the radioligand as it moves through the subject [176]. To capture a time course, images are segmented
across time for a major arterial vessel and the tissue(s) of interest, and when combined with the kinetic
tracer model, the theoretical distribution of the tracer over the scanning period can be quantified [176].
In this system, the mathematical model defines the relationship between the measurable imaging
data and relates this to the physiological parameters that affect the uptake and metabolism of the
molecular tracer following the conservation of mass [176,177]. A number of literature sources provide a
comprehensive presentation of modeling alternatives [178–183], where some are described as stochastic
or non-compartmental and require minimal assumptions concerning the underlying physiology of the
tracer’s uptake and metabolism [184]. Alternatively, a class of models that specify the physical locations,
biochemical forms of the tracer, and also include the concentration gradients that exist, have been
developed to describe the capillary–tissue exchange of a tracer and are termed distributed [185–191].
A class of model that is between a stochastic and distributed model is the compartmental model,
that attempts to retain underlying physiology but do not include concentration gradients [176,177].
In PET (or SPECT), a compartmental model utilizes the measurements of radioactivity in a specific
organ, region, or even pixel collected via the scanner with time. If the tracer enters and exits the organ
via the blood, then the tracer kinetics in other body regions need not be considered to evaluate the
physiological traits of the organ of interest [176,177], thus allowing each region or pixel to be analyzed
independently. The type of tracer kinetic model to select and the relationship to the underlying
physiology is beyond the scope of this review, and the reader is referred to excellent literature sources
on this topic [176,177]. Regardless of the model selected, the end product is the generation of rate
constants that describe the flux of radioactivity in and out of theoretical compartments of interest.
Below are block diagrams for the 4 most common models used in tracer kinetic modelling (Figure 3):
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while (B) represents a similar model, but the tracer is not trapped in the C1 compartment, thus 
allowing efflux back into the blood as with radioactive water studies [178] (Equation 7). In diagram 
(C), the model has been used to describe the binding of ligands to receptor systems, where the C1 
compartment represents the interstitial space, and C2 is the receptor complex on the tissue of interest, 
such as for glucose metabolism [193] or P2X7 receptor binding [173] (Equations 8–9). Lastly, (D) has 
been used to describe binding to the receptor system described in (C), but the C3 compartment 
represents the non-specific binding (Equations 10–12) [194]. 
Given the models described in Figure 3, the following partial differential equations can be 
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= k3 ∗C1(t) − k4 ∗C2(t) (11)
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= k5 ∗C1(t) − k6 ∗C3(t) (12)
where, Equations (6)–(12), correspond to the block diagrams A, B, C, and D shown in Figure 3,
respectively. Typically, these equations are solved numerically, to yield the rate constants K1–k6,
and can be reformulated to yield physiological information as follows:
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Q, Kd, Bp, NS, and Vt are the tissue perfusion, equilibrium dissociation rate constant, equilibrium
binding potential, non-specific binding, and total volume of distribution of the receptors in the tissues.
These methods provide the only non-invasive means to determine these parameters for the receptors
in vivo, and are the fundamental basis for target specificity, target sensitivity, and high contrast to
noise, and are necessary for understanding the pathophysiological trajectory of disease. Moreover,
when combined with therapeutics, which directly modulate the receptor system, the molecular probe
provides pharmacodynamic readouts of target engagement and therapeutic responses.
The administration of any compound, which is either experimental or for clinical trials, requires
extensive information to be generated in preparation for human administration to ensure a complete
understanding of the benefit to risk ratio profile [195]. In order to obtain these data, preclinical
studies are performed in model systems in vivo and/or in vitro, where a more complete understanding
of the compounds kinetics, distribution, and toxicology are measured [195,196]. In the case of a
radiopharmaceutical, the kinetics of the tracer are obtained by the aforementioned dynamic study,
where the tracer kinetics are derived from the image time series. The biodistribution, by contrast,
may be obtained by either post-mortem determination of the tissue accumulation or via image-based
quantitation. In traditional post-mortem technique, either at the completion of a PET (or SPECT)
scan, or in a dedicated cohort which has been injected with the radiotracer, major organs (i.e., brain,
heart, lungs, liver, kidneys, spleen, pancreas, small and large intestines, bladder, and skeletal muscle)
from the test subject are extracted, weighed, and total activity measured to determine the amount of
radiopharmaceutical which is present per gram of tissue [195]. Similarly, recent work with theranostic
agents has utilized image-based distribution approaches, where regions of interest are drawn on PET
images, guided by co-registered anatomical CT or MRI images [196], and yield similar endpoints to
the post-mortem analyses conducted ex vivo. Regardless of the approach, the end goal in each of
these cases is the determination of tissue radiopharmaceutical exposure, and therefore the radiation
dosimetry of the molecular probe. Radiation dosimetry quantifies the amount of ionizing radiation
deposited in a tissue, and is influenced by the energy, size, charge, half-life, administered dose, and the
dose rate of the radioactive material [197,198], and is used to determine the relative risk to the subject.
To determine this, data collected from preclinical biodistribution studies can be scaled allometrically,
and dosimetry estimates extrapolated to humans using tools such as IDAC [199], OLINDA [200],
and MIM SurPlan [201]. Independent of the approach, the end goal is the determination of the
tissue dosimetry estimates to help guide the use of the new radiopharmaceutical by researchers and
clinicians alike.
10. Conclusions
There are presently no fully adequate ways to quantify beta cell mass in vivo or to target protective
agents specifically to the beta cells; this hampers the understanding of the pathogenesis of diabetes and
the development of novel therapies to preserve beta cells and/or to induce their proliferation. To solve
this problem, novel and specific beta cell biomarkers must be identified to allow adequate in vivo
imaging by methods such as PET and, in future steps, specific delivery of therapeutic agents. The ideal
biomarker should enable the development of tracers for measurements based on minimally invasive
technology, allowing repeated examinations over time. The eventual success of beta cell imaging will
allow the stratification of patients at early diagnosis (i.e., define the amount of remaining beta cells and
follow them up as the disease evolves) and, crucially, to assess and validate novel therapies aiming to
preserve and/or restore beta cell mass, including islet transplantation, immune modulation and new
agents that induce the generation of novel beta cells. We are not there yet, but the presently discussed
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recent advances in the field, allied to logic and a step-by-step approach to identify and validate novel
tracers for beta cell imaging, augurs well for the future of the field.
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3D Three-dimensional
BCM Beta cell mass
DOTA Dodecane tetraacetic acid
DOTATATE DOTA-0-Tyr3-octreotate
DOTATOC (DOTA0-Phe1-Tyr3) octreotide
DPP6 Dipeptidyl peptidase 6
DTBZ Dihydrotetrabenazine
DTPA Diethylenetriaminepenta-acetic acid
FOV Field of view
FXYD2 FXYD domain-containing ion transport regulator 2
GLP-1 Glucagon-like peptide-1
GLP-1R Glucagon-like peptide-1 receptor
HTP Hydroxytryptophan
HTS High throughput screening
IEQ Islet equivalent
mAb Monoclonal antibody
MRI Magnetic resonance imaging
Nb Nanobody
NOD-SCID Nonobese diabetic/severe combined immunodeficiency
NOEL No effect level
NOTA 1,4,7-triazacyclononane-1,4,7-triacetic acid
PET Positron emission tomography
PD-L1 Programmed death-ligand 1
PSMA Prostate-specific membrane antigen
SNR Signal-to-noise ratio
SPECT Single-photon emission computed tomography
T1D Type 1 diabetes
T2D Type 2 diabetes
USPIO Ultra-small particles of iron oxide
VMAT2 Vesicular monoamine transporter 2
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